| Rewiring of genetic networks in response to DNA damage S Bandyopadhyay, M Mehta, D Kuo, MK Sung, R Chuang, EJ Jaehnig, ... Science 330 (6009), 1385-1389, 2010 | 548 | 2010 |
| Computational tools for metabolic engineering WB Copeland, BA Bartley, D Chandran, M Galdzicki, KH Kim, SC Sleight, ... Metabolic engineering 14 (3), 270-280, 2012 | 125 | 2012 |
| Increasing gender diversity in the STEM research workforce CW Greider, JM Sheltzer, NC Cantalupo, WB Copeland, N Dasgupta, ... Science 366 (6466), 692-695, 2019 | 92 | 2019 |
| Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia … AM Zeidan, J Cavenagh, MT Voso, D Taussig, M Tormo, I Boss, ... Blood 134, 829, 2019 | 83 | 2019 |
| Mathematical modeling and synthetic biology D Chandran, WB Copeland, SC Sleight, HM Sauro Drug Discovery Today: Disease Models 5 (4), 299-309, 2008 | 81 | 2008 |
| A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML AM Zeidan, I Boss, CL Beach, WB Copeland, E Thompson, BA Fox, ... Blood Advances 6 (7), 2219-2229, 2022 | 63 | 2022 |
| Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials SA Danziger, M McConnell, J Gockley, MH Young, A Rosenthal, ... PLoS Medicine 17 (11), e1003323, 2020 | 52 | 2020 |
| A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes AM Zeidan, I Boss, CL Beach, WB Copeland, E Thompson, BA Fox, ... Blood Advances 6 (7), 2207-2218, 2022 | 41 | 2022 |
| Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia. AM Zeidan, IW Boss, CL Beach, WB Copeland, EG Thompson, BA Fox, ... | 5 | 2021 |
| Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma MH Young, G Pietz, E Whalen, W Copeland, E Thompson, BA Fox, ... Scientific Reports 11 (1), 16460, 2021 | 5 | 2021 |
| Baseline and on-treatment bone marrow microenvironments predict myeloma patient outcomes and inform potential intervention strategies SA Danziger, M McConnell, J Gockley, M Young, A Rosenthal, F Schmitz, ... Blood 132, 1882, 2018 | 4 | 2018 |
| Comprehensive immune profiling from peripheral blood and bone marrow in newly diagnosed and relapsed/refractory multiple myeloma patients reflects differences in immune subsets … GE Pietz, M Tometsko, WB Copeland, E Whalen, F Schmitz, ... Blood 132 (Supplement 1), 3161-3161, 2018 | 3 | 2018 |
| Deep immunoprofiling of the bone marrow microenvironmental changes underlying the multistep progression of multiple myeloma MH Young, SA Danziger, A Fitch, F Schmitz, J Gockley, M McConnell, ... Blood 132, 243, 2018 | 2 | 2018 |
| Biological probes to measure transcription dynamics in E. coli WB Copeland | 2 | 2014 |
| Deconvolution of the immune microenvironment can predict the outcome of myeloma patients and inform potential intervention strategies S Danziger, AP Dervan, F Schmitz, BA Walker, W Copeland, A Fitch, ... Blood 130, 1751, 2017 | 1 | 2017 |
| Populations of triple negative and hormone receptor positive HER2 negative breast tumors share immune gene profiles S Stanton, F Schmitz, W Copeland, J DellAringa, K Newhall, M Disis Research Square, rs. 3. rs-4542494, 2024 | | 2024 |
| Populations of Triple Negative and Hormone Receptor Positive HER2 Negative Breast Tumors Share Immune Gene Profi les F Schmitz, WB Copeland, JD Aringa, K Newhall, ML Disis, SE Stanton Journal ISSN 2766, 2276, 2024 | | 2024 |
| Do chemical language models provide a better compound representation? M Torrisi, S Asadollahi, A Vega de León, K Wang, W Copeland bioRxiv, 2023.11. 07.566025, 2023 | | 2023 |
| A Randomized Phase 2 Trial of Azacitidine±Durvalumab as First-line Therapy for Higher-Risk Myelodysplastic Syndromes AM Zeidan, IW Boss, CL Beach, WB Copeland, EG Thompson, BA Fox, ... Blood Advances, 2021 | | 2021 |
| Standardizing promoter activity through quantitative measurement of transcriptional dynamics WB Copeland, HM Sauro Platinum Sponsor, 23, 0 | | |
